Nervous system

Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting

Retrieved on: 
Wednesday, January 17, 2024

REDWOOD CITY, Calif., Jan. 17, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.

Key Points: 
  • Results will be presented at the 2024 North American Neuromodulation Society (NANS) Annual Meeting held from January 18-21, 2024 at Caesars Palace Las Vegas.
  • A total of 25 scientific abstracts reviewing clinical results for 10 kHz Therapy™, including four podium presentations and 21 posters, will be presented at the conference.
  • "The growing body of clinical evidence from our 25 scientific abstracts displays the substantial benefits of 10 kHz Therapy and we look forward to continuing to treat underserved patient populations suffering from debilitating chronic pain."
  • The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

What is frostbite, what are the signs and how should we treat it?

Retrieved on: 
Wednesday, January 17, 2024

Thankfully, with the right preventative and protective measures, the human body can survive these icy temperatures.

Key Points: 
  • Thankfully, with the right preventative and protective measures, the human body can survive these icy temperatures.
  • Here’s what you need to know about identifying and treating the most common cold injury: frostbite.
  • However, despite our bodies’ inherent temperature controls, without the right protection, we might still be vulnerable to cold weather injuries.
  • For frostbite to occur, exposed body parts need to be subjected to a temperature that is below minus 0.55°C.
  • At this temperature it will take several hours for exposed skin to become frostbitten.
  • For example, temperatures in the -20s can cause frostbite on exposed skin in under 30 minutes.

Who does it affect?

  • However, with the global population beginning to live in harsher environments and an increase in winter and snow sports, this is likely to increase in the general population.
  • Reduced ability to sense the cold also increases the frostbite vulnerability of those who’ve had a stroke or have peripheral nerve damage.
  • The consumption of alcohol also reduces blood pressure, which may also reduce the amount of blood pumped to extremities.

Symptoms

  • Preserving the core body temperature is key to keeping the brain, heart, kidneys and lungs functioning and preventing hypothermia.
  • This cooling brings about tingling and numbness of the exposed areas, and skin flushes red or white as the body frantically tries to rewarm itself.
  • This initial stage is known as frostnip, and, although uncomfortable, leaves no permanent damage to tissues.

Treatment and prevention

  • For frostbite, immediate medical treatment should be sought – sadly the pain of recovery is often far worse than the injury.
  • Rewarming is the process of bringing the affected parts back to functioning body temperature.
  • However, where ice crystals have damaged tissue, blisters are common and the nerves become hypersensitive, causing excruciating pain.


Adam Taylor does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Autonomix Medical, Inc. Successfully Completes Preclinical Safety Study to Support Program Advancement into First-in-Human Clinical Study to Treat Pancreatic Cancer Pain Through Transvascular Ablation

Retrieved on: 
Friday, January 12, 2024

THE WOODLANDS, TX, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced successful completion of an animal safety study evaluating the Company’s proprietary ablation technology. All safety inputs for the study were met. No procedure-related side effects have been reported.

Key Points: 
  • The safety study was designed to assess acute safety and feasibility of tissue ablation in a porcine multi-arterial model.
  • Findings in the study demonstrated successful energy delivery, with no acute complications using several of the Company’s proprietary ablation catheters.
  • “We are very pleased with the outcome of this important safety study, and we continue to execute on developing our potentially groundbreaking technology.
  • The successful completion of this preclinical safety study provides us with supportive data as we advance toward our first-in-human clinical study, a catalytic milestone for Autonomix,” commented Lori Bisson, Chief Executive Officer of Autonomix.

Autonomix Medical, Inc. Completes Formation of Engineering Development Team and Provides Project Update

Retrieved on: 
Thursday, January 11, 2024

THE WOODLANDS, TX, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the completion of its engineering development team formation and provided an engineering update.

Key Points: 
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “We continue to execute on advancing the development of our technology.
  • To drive the advancement of its proprietary technology, the Company has appointed Marco Bedoya as Director of Product Development.
  • Additionally, Autonomix has engaged the following engineering firms:
    Emphysys A Tecan Group Company : Leading global provider blending fundamental science and engineering to deliver limitless technology development.
  • Kaleidoscope Innovation : Provides medical, consumer and industrial clients with full-service insights, design, human factors and product development.

Autonomix Medical, Inc. to Present at the Startup Investing Webinar

Retrieved on: 
Thursday, January 11, 2024

THE WOODLANDS, TX, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix will participate in the Startup Investing Webinar featuring Autonomix, Knightscope, and Infinity Fuel on Thursday, January 11, 2024 at 2:00 PM ET.

Key Points: 
  • Live webcast roundtable discussion featuring Autonomix, Knightscope, and Infinity Fuel on Thursday, January 11th at 2:00 PM ET
    THE WOODLANDS, TX, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix will participate in the Startup Investing Webinar featuring Autonomix, Knightscope, and Infinity Fuel on Thursday, January 11, 2024 at 2:00 PM ET.
  • As part of the roundtable event, Autonomix will discuss its revolutionary catheter-based sensing technology in development to do two things: sense neural signals associated with pain or disease and precisely target those nerves for treatment.
  • Autonomix believes this technology is a better alternative to the current approaches commonly used today, where doctors either rely on systemic drugs like opioids that lose effectiveness and have unwanted side effects or treat suspected areas blindly in hopes of hitting the right nerves, an approach that is often inaccurate and can miss the target and even cause collateral damage to surrounding parts of the body.
  • For more information about the Startup Investing Webinar and to register, visit the event website here .

Innatera unveils its groundbreaking ultra-low power neuromorphic microcontroller at CES 2024

Retrieved on: 
Thursday, January 11, 2024

DELFT, Netherlands, Jan. 11, 2024 /PRNewswire/ -- Innatera, the pioneer in ultra-low power intelligence, is proud to announce the unveiling of its neuromorphic microcontroller - the Spiking Neural Processor T1 - at CES 2024.

Key Points: 
  • DELFT, Netherlands, Jan. 11, 2024 /PRNewswire/ -- Innatera, the pioneer in ultra-low power intelligence, is proud to announce the unveiling of its neuromorphic microcontroller - the Spiking Neural Processor T1 - at CES 2024.
  • At CES 2024, Innatera will showcase the Spiking Neural Processor T1 through live demonstrations of radar and audio applications from Innatera's partners.
  • The Spiking Neural Processor is a versatile neuromorphic processing technology that mimics the brain's mechanisms for processing sensory data.
  • To learn more about Innatera and book a meeting at CES, please visit

GIGABYTE Debuts Next-Gen 16-inch AI Gaming Laptops at CES 2024

Retrieved on: 
Monday, January 8, 2024

TAIPEI, Jan. 8, 2024 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, proudly presents the full lineup of next-gen AI Gaming Laptops at CES 2024, leading featured models – AORUS 16X and GIGABYTE G6X.

Key Points: 
  • TAIPEI, Jan. 8, 2024 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, proudly presents the full lineup of next-gen AI Gaming Laptops at CES 2024, leading featured models – AORUS 16X and GIGABYTE G6X.
  • These AI Gaming Laptops are built to accomplish generative AI workloads faster, while providing longer battery life and seamless AI software experience.
  • As a significant milestone in the era of AI, GIGABYTE AI Gaming Laptops deliver up to 20 times faster performance for generative AI workloads by adopting NVIDIA GeForce RTX™ 40 series laptop GPUs.
  • Leading the new lineup of GIGABYTE AI Gaming Laptops, the AORUS 16X and GIGABYTE G6X both feature modern 16-inch displays in a 16:10 aspect ratio, delivering immersive visuals and gaming advantages.

GIGABYTE Debuts Next-Gen 16-inch AI Gaming Laptops at CES 2024

Retrieved on: 
Monday, January 8, 2024

TAIPEI, Jan. 8, 2024 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, proudly presents the full lineup of next-gen AI Gaming Laptops at CES 2024, leading featured models – AORUS 16X and GIGABYTE G6X.

Key Points: 
  • TAIPEI, Jan. 8, 2024 /PRNewswire/ -- GIGABYTE, the world's leading computer brand, proudly presents the full lineup of next-gen AI Gaming Laptops at CES 2024, leading featured models – AORUS 16X and GIGABYTE G6X.
  • These AI Gaming Laptops are built to accomplish generative AI workloads faster, while providing longer battery life and seamless AI software experience.
  • As a significant milestone in the era of AI, GIGABYTE AI Gaming Laptops deliver up to 20 times faster performance for generative AI workloads by adopting NVIDIA GeForce RTX™ 40 series laptop GPUs.
  • Leading the new lineup of GIGABYTE AI Gaming Laptops, the AORUS 16X and GIGABYTE G6X both feature modern 16-inch displays in a 16:10 aspect ratio, delivering immersive visuals and gaming advantages.

miRNA Sequencing And Assay Market Research Report 2023: Global Size, Share & Trends Analysis and Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 8, 2024

The "miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service (Library Preparation Kits), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service (Library Preparation Kits), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global miRNA sequencing and assay market size is expected to reach USD 823.5 Million by 2030, registering a CAGR of 13.3% from 2023 to 2030.
  • Thus, miRNA sequence analysis is significantly employed for gene regulation analysis in clinical disorders.
  • For instance, an article published in frontiers, in March 2022, stated that blood-based miRNA biomarkers could be used to correlate brain-based miRNA expression.

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Retrieved on: 
Monday, January 8, 2024

Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vimpat, lacosamide, Date of authorisation: 29/08/2008, Revision: 48, Status: Authorised